{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T01:10:10Z","timestamp":1778202610326,"version":"3.51.4"},"reference-count":32,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.urolonc.2026.111089","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T11:32:11Z","timestamp":1775129531000},"page":"61-69","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk stratification of Ta high-grade non\u2013muscle-invasive bladder cancer: Insights from a multicenter cohort study"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-8050-9388","authenticated-orcid":false,"given":"Paolo","family":"Zaurito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Scilipoti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mattia","family":"Longoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"de Angelis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksander","family":"\u015alusarczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Viti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"Santangelo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Tremolada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Soria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Pradere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wojciech","family":"Krajewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"D\u2019Andrea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Mari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco Del","family":"Giudice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renate","family":"Pichler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Daniel","family":"Subiela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gautier","family":"Marcq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Gallioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Afferi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Mastroianni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Simone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Albisinni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura S.","family":"Mertens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekaterina","family":"Laukhtina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Oberneder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Luis Rodr\u00edguez","family":"Elena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Aranda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso Lafuente","family":"Puentedura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge Ca\u00f1o","family":"Velasco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Contieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodolfo","family":"Hurle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichiro","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piotr","family":"Radziszewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Gontero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morgan","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Montorsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Salonia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Moschini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.urolonc.2026.111089_bib0001","doi-asserted-by":"crossref","first-page":"7892","DOI":"10.1245\/s10434-023-14051-9","article-title":"Cancer-specific survival of patients with non-muscle-invasive bladder cancer: a population-based analysis","volume":"30","author":"\u015alusarczyk","year":"2023","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2026.111089_bib0002","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.euo.2023.01.004","article-title":"Prognosis of primary papillary ta grade 3 bladder cancer in the non-muscle-invasive spectrum","volume":"6","author":"Beijert","year":"2023","journal-title":"Eur Urol Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.111089_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.111089_bib0004","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.eururo.2024.07.027","article-title":"European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)-a summary of the 2024 guidelines update","volume":"86","author":"Gontero","year":"2024","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2026.111089_bib0005","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","article-title":"European Association of Urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC guidelines panel","volume":"79","author":"Sylvester","year":"2021","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2026.111089_bib0006","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/JU.0000000000003846","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline: 2024 amendment","volume":"211","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2026.111089_bib0007","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.euo.2022.05.005","article-title":"Intermediate-risk non-muscle-invasive bladder cancer: updated consensus definition and management recommendations from the international bladder cancer group","volume":"5","author":"Tan","year":"2022","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2026.111089_bib0008","doi-asserted-by":"crossref","first-page":"132.e7","DOI":"10.1016\/j.urolonc.2020.07.017","article-title":"Primary Ta high grade bladder tumors: determination of the risk of progression","volume":"39","author":"Quhal","year":"2021","journal-title":"Urol Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111089_bib0009","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0022-5347(05)67972-4","article-title":"Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome","volume":"163","author":"Herr","year":"2000","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2026.111089_bib0010","doi-asserted-by":"crossref","first-page":"335","DOI":"10.7326\/M18-2782","article-title":"Balancing protection and free movement of personal data: the new European Union general data protection regulation","volume":"170","author":"Bentzen","year":"2019","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111089_bib0011","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/bju.16675","article-title":"Outcomes of BCG vs upfront radical cystectomy for high-risk non-muscle-invasive bladder cancer","volume":"136","author":"Scilipoti","year":"2025","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111089_bib0012","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1007\/s00345-024-05342-1","article-title":"The role of re-transurethral resection of bladder tumor in patients with TaHG non muscle invasive bladder cancer","volume":"42","author":"Scilipoti","year":"2024","journal-title":"World J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111089_bib0013","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.euf.2025.04.033","article-title":"Long-term oncological outcomes for patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Gu\u00e9rin (BCG): a comparative analysis of adequate versus inadequate bcg treatment","volume":"12","author":"Scilipoti","year":"2026","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.urolonc.2026.111089_bib0014","unstructured":"BCG live package insert (BCG live for intravesical use) TICE\u00ae BCG. 2009."},{"key":"10.1016\/j.urolonc.2026.111089_bib0015","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER): BCG unresponsive nonmuscle invasive bladder can- cer: developing drugs and biologics for treat- ment guidance for industry. U.S. Food and Drug Administration 2018. Accessed November 2, 2025. Available at https:\/\/www.fda.gov\/media\/101468\/download."},{"issue":"16","key":"10.1016\/j.urolonc.2026.111089_bib0016","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","article-title":"Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group","volume":"34","author":"Kamat","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.111089_bib0017","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.eururo.2011.05.045","article-title":"Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review","volume":"60","author":"van den Bosch","year":"2011","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2026.111089_bib0018","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Control Clin Trials"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111089_bib0019","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1200\/JCO.1991.9.1.191","article-title":"Median follow-up in clinical trials","volume":"9","author":"Shuster","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.111089_bib0020","series-title":"R: A language and environment for statistical computing","year":"2022"},{"issue":"5","key":"10.1016\/j.urolonc.2026.111089_bib0021","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/bju.16780","article-title":"Contemporary outcomes in non-muscle-invasive bladder cancer: a large European multicentre study","volume":"136","author":"Longoni","year":"2025","journal-title":"BJU Int."},{"issue":"5","key":"10.1016\/j.urolonc.2026.111089_bib0022","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.euo.2025.03.007","article-title":"Oncological outcomes in Bacillus Calmette-Gu\u00e9rin-na\u00efve high-risk non-muscle-invasive bladder cancer patients: a systematic review on current treatment strategies and future perspectives","volume":"8","author":"Longoni","year":"2025","journal-title":"Eur Urol Oncol."},{"issue":"2","key":"10.1016\/j.urolonc.2026.111089_bib0023","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/JU.0000000000002678","article-title":"All high-grade ta tumors should be classified as high risk: bacillus Calmette-Gu\u00e9rin response in high-grade Ta tumors","volume":"208","author":"Bree","year":"2022","journal-title":"J Urol"},{"issue":"6 Suppl 1","key":"10.1016\/j.urolonc.2026.111089_bib0024","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.urology.2005.06.135","article-title":"High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder","volume":"66","author":"Sylvester","year":"2005","journal-title":"Urology"},{"issue":"2","key":"10.1016\/j.urolonc.2026.111089_bib0025","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.euo.2023.02.003","article-title":"Where to draw the line: stratifying risk for high-grade Ta bladder cancer","volume":"6","author":"St-Laurent","year":"2023","journal-title":"Eur Urol Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.111089_bib0026","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.eururo.2025.12.022","article-title":"Efficacy and safety of checkpoint inhibitors combined with bacillus Calmette-Gu\u00e9rin (BCG) in BCG-na\u00efve High-risk non-muscle-invasive bladder cancer: synthesis of evidence from the ALBAN, CREST, and POTOMAC trials","volume":"89","author":"Scilipoti","year":"2026","journal-title":"Eur Urol."},{"issue":"5","key":"10.1016\/j.urolonc.2026.111089_bib0027","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","article-title":"Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model","volume":"182","author":"Fernandez-Gomez","year":"2009","journal-title":"J Urol"},{"issue":"16","key":"10.1016\/j.urolonc.2026.111089_bib0028","doi-asserted-by":"crossref","first-page":"4599","DOI":"10.1158\/1078-0432.CCR-21-0205","article-title":"Identification of a novel inflamed tumor microenvironment signature as a predictive biomarker of bacillus Calmette-Gu\u00e9rin immunotherapy in non-muscle-invasive bladder cancer","volume":"27","author":"Damrauer","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.urolonc.2026.111089_bib0029","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1097\/JU.0000000000003126","article-title":"Urinary analysis of FGFR3 and TERT gene mutations enhances performance of cxbladder tests and improves patient risk stratification","volume":"209","author":"Lotan","year":"2023","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.111089_bib0030","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/JU.0000000000002740","article-title":"Sequential intravesical gemcitabine and docetaxel for bacillus Calmette-Gu\u00e9rin-na\u00efve high-risk nonmuscle-invasive bladder cancer","volume":"208","author":"McElree","year":"2022","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111089_bib0031","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/JU.0000000000003977","article-title":"A phase 2 trial of intravesical gemcitabine and docetaxel in the treatment of Bacillus Calmette-Gu\u00e9rin\u2012na\u00efve nonmuscle-invasive urothelial carcinoma of the bladder","volume":"212","author":"Patel","year":"2024","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111089_bib0032","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/bju.16675","article-title":"Outcomes of BCG vs upfront radical cystectomy for high-risk non-muscle-invasive bladder cancer","volume":"136","author":"Scilipoti","year":"2025","journal-title":"BJU Int"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926001006?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926001006?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:29:36Z","timestamp":1778200176000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926001006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1078143926001006"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.111089","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk stratification of Ta high-grade non\u2013muscle-invasive bladder cancer: Insights from a multicenter cohort study","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.111089","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}